Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Filgotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 16/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 15/20 | 1.00 |
| ▸ | JAK3 known ✓ | P52333 | 4/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 3/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | STAT1 | P42224 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Filgotinib SCHEMBL28650869 | 0.99 | JAK2 (0.98) | JAK2JAK1JAK3TYK2STK10 | |
| Filgotinib SCHEMBL29389789 | 0.98 | JAK2 (0.96) | JAK2JAK1JAK3TYK2STK10 | |
| Filgotinib SCHEMBL20496651 | 0.95 | JAK2 (0.90) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL18397544 | 0.93 | JAK1 (0.86) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL2237580 | 0.90 | JAK2 (1.00) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL218472 | 0.90 | JAK1 (1.00) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL218626 | 0.89 | JAK2 (1.00) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL2237614 | 0.89 | JAK1 (1.00) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL2239378 | 0.89 | JAK2 (0.85) | JAK2JAK1JAK3TYK2STK10 | |
| SCHEMBL18405534 | 0.88 | JAK2 (0.84) | JAK2JAK1JAK3TYK2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260137953-A1 | METHOD FOR TARGETED TREATING DERMATOSES | STRATA SKIN SCIENCES INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026105679-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR SKIN DISORDER | 国立大学法人神戸大学 | 2026-05-21 | — | — | WO | claimed |
| WO-2026107075-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | claimed |
| WO-2026090300-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20220062337-A1 | TREATMENT AND DIAGNOSIS OF AUTOANTIBODY-MEDIATED EYE DISEASES | UNIV ILLINOIS (US) | 2022-03-03 | — | — | US | claimed |
| WO-2022038365-A2 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | WO | claimed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |
| CN-113773322-B | Preparation method of Filgotinib | 奥锐特药业(天津)有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022023490-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-3944859-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | Assistance Publique Hôpitaux de Paris (FR) | 2022-02-02 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | claimed |